magrolimab + venetoclax + azacitidine

Magrolimab + venetoclax + azacitidine is an investigational **three-drug combination** therapy evaluated for the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. **Magrolimab** is a monoclonal antibody targeting CD47, a "don't eat me" signal on tumor cells, augmenting phagocytosis by macrophages. **Venetoclax** is a selective BCL-2 inhibitor, promoting apoptosis in malignant cells. **Azacitidine** is a DNA methyltransferase inhibitor (a hypomethylating agent) that modifies epigenetic regulation and increases pro-phagocytic signals. Preclinical and early clinical studies show that this combination can synergistically induce cancer cell death by both increasing phagocytosis and apoptosis in AML cells. The regimen is being studied primarily in older or unfit adults with AML, but has also been evaluated in relapsed/refractory disease settings. In phase 3 clinical studies (such as ENHANCE-3), the triplet regimen did not demonstrate superior overall survival compared to venetoclax plus azacitidine alone, and there was an increased incidence of fatal adverse events with the triplet[1][2][3][8].